World Journal of Laparoscopic Surgery with DVD

Register      Login

VOLUME 10 , ISSUE 1 ( January-April, 2017 ) > List of Articles

RESEARCH ARTICLE

Obesity-related Metabolic Comorbidities Remission in Postbariatric Surgery Patients

Evelyn A Dorado, Maria V Lopez, Viviana O Martin

Citation Information : Dorado EA, Lopez MV, Martin VO. Obesity-related Metabolic Comorbidities Remission in Postbariatric Surgery Patients. World J Lap Surg 2017; 10 (1):30-34.

DOI: 10.5005/jp-journals-10033-1298

Published Online: 01-04-2017

Copyright Statement:  Copyright © 2017; Jaypee Brothers Medical Publishers (P) Ltd.


Abstract

Introduction

Obesity-related diseases (ORD) are associated with a decrease in the quality of life and life expectancy of patients. The remission of these pathologies after bariatric surgery is not the same in all patients.

Objectives

To evaluate the remission of the principal ORD in patients who underwent bariatric surgery.

Materials and methods

Retrospective analysis of patients with morbid obesity and ORD (hypertension, diabetes mellitus, dyslipidemia or obstructive sleep apnea and hypoapnea syndrome) who received bariatric surgery between January 2014 and January 2016. Patients had two surgical options: Laparoscopic sleeve gastrectomy (LSG) or laparoscopic Roux-en-Y gastric bypass (LRYGB). Follow-up was performed after 1, 6, and 12 months per the first year after surgery, recording data, such as percentage of excess weight lost (%EWL), percentage of total body weight lost, and partial or total ORD remission.

Results

Out of a total of 23 patients, 52% (12) were females and the average age was 44 ± 13 years, 17 (74%) received LSG and 6 (26%) LRYGB. The average initial body mass index was 43 ± 4.3 kg/m2, the %EWL at 1, 6, and 12 months was 35.4 ± 15.2, 62.5 ± 17.5, and 79.1 ± 20.2 respectively. Comorbidities remission was found in 95.6% of patients (22), partial resolution in 32%, and complete in 68%. A total of 52.1% of remissions were reported in the first month postsurgery.

Conclusion

Bariatric surgery has proved to be the most effective method for reducing and sustaining weight loss in the long-term and comorbidities remission. A decrease of 50% of EWL has a positive impact in terms of discontinuing medications and normalizing the patient's biochemical profile.

How to cite this article

Dorado EA, Lopez MV, Martin VO. Obesity-related Metabolic Comorbidities Remission in Postbariatric Surgery Patients. World J Lap Surg 2017;10(1):30-34.


PDF Share
  1. Laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy achieve comparable weight loss at 1 year. Am Surg 2012 Dec;78(12):1325-1328.
  2. Overweight and obesity worldwide now estimated to involve 1.7 billion people. Obes Surg 2003 Jun;13(3):329-330.
  3. Bariatric surgery for morbid obesity. Obes Surg 2000 Oct;10(5):391-401.
  4. Economic benefits of bariatric surgery. Obes Surg 2012 Feb;22(2):266-270.
  5. Entidades regionales se unen contra la obesidad. El Tiempo; 2015.
  6. Impact of bariatric surgery on comorbidities. Surg Clin North Am 2011 Dec;91(6):1295-1312, ix.
  7. The potential effects of obesity on social security claiming behavior and retirement benefits. J Gerontol B Psychol Sci Soc Sci 2016 Apr 4. pii:gbw016.
  8. Bariatric surgery versus intensive medical therapy for diabetes – 3-year outcomes. N Engl J Med 2014 May;370(21):2002-2013.
  9. Bariatric surgery may improve employment status in unemployed, underserved, severely obese patients. Obes Surg 2014 May;24(5):692-695.
  10. Paid work increases and state benefit claims decrease after bariatric surgery. Obes Surg 2007 Apr;17(4):434-437.
  11. Reduction in obesity-related comorbidities: is gastric bypass better than sleeve gastrectomy? Surg Endosc 2013 Apr;27(4):1273-1280.
  12. Early outcomes of bariatric surgery in patients with metabolic syndrome: an analysis of the bariatric outcomes longitudinal database. J Am Coll Surg 2012 Apr;214(4):550-557.
  13. Predictors of hypertension remission and recurrence after bariatric surgery. Am J Hypertens 2016 May;29(5):653-659.
  14. Association between bariatric surgery and long-term survival. JAMA 2015 Jan;313(1):62-70.
  15. Impacto de la cirugia bariatrica sobreel sindrome metabolico. Cir Endosc 2008 Oct-Dec;9(4):177-182.
  16. The economic impact of weight regain. Gastroenterol Res Pract 2013;2013:379564.
  17. Reduced survival in bariatric surgery candidates delayed or denied by lack of insurance approval. Am Surg 2016 Feb;82(2):166-170.
  18. Impact of bariatric surgery on the medical management and costs of obese patients in France: an analysis of a national representative claims database. Obes Surg 2015 Jun;25(6):986-996.
  19. Impact of restrictive (sleeve gastrectomy) vs hybrid bariatric surgery (Roux-en-Y gastric bypass) on lipid profile. Obes Surg 2012 Aug;22(8):1268-1275.
  20. The effect of bariatric surgery type on lipid profile: an age, sex, body mass index and excess weight loss matched study. Obes Surg 2016 May;26(5):1041-1047.
  21. Non-alcoholic fatty liver disease resolution following sleeve gastrectomy. Surg Endosc 2016 May;30(5):1983-1987.
  22. Early impact of bariatric surgery on type II diabetes, hypertension, and hyperlipidemia: a systematic review, meta-analysis and meta-regression on 6,587 patients. Obes Surg 2014 Apr;24(4):522-528.
  23. Bariatric surgery: a systematic review and meta-analysis. JAMA 2004 Oct;292(14):1724-1737.
  24. Metabolic/bariatric surgery worldwide 2011. Obes Surg 2013 Apr;23(4):427-436.
  25. Comorbidities remission after Roux-en-Y Gastric Bypass for morbid obesity is sustained in a long-term follow-up and correlates with weight regain. Obes Surg 2012 Oct;22(10):1580-1585.
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.